PhoreMost Advances Oncology Program Towards Clinical Trials
Biotechnology firm PhoreMost announced its lead oncology program, PMC-001, is progressing towards human trials, appointing a Chief Medical Officer to oversee development.
London, UK – Biotechnology company PhoreMost has announced significant progress in its oncology drug development pipeline. The company's lead program, PMC-001, a next-generation oral small molecule targeting microtubules, is advancing towards first-in-human clinical trials. This development targets both primary brain cancers and secondary brain metastases.
PhoreMost focuses on translating scientific discoveries into cancer therapeutics. PMC-001 is designed to overcome limitations of existing microtubule-targeting agents, such as taxanes, by offering oral bioavailability and potent blood-brain barrier penetration—critical factors for treating brain tumors which represent a significant unmet medical need.
Preclinical studies have shown PMC-001 to possess strong anti-tumor efficacy and good tolerability across various models. Manufacturing of the drug substance is complete, and regulatory filings are being prepared to initiate clinical trials. The program originated from a collaboration with Sentinel Oncology.
To support this advancement, PhoreMost has appointed Dr. Gabriel Fox as Consulting Chief Medical Officer. Dr. Fox brings extensive industry experience in drug development and will lead the clinical strategy for PMC-001 as it moves into human testing.